These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from April 11 through April 17, 2024. Source: VerityData
Increases in Holdings
MasterCraft Boat Holdings Coliseum Capital Management increased its stake in the boat manufacturer to 2,224,284 shares. Coliseum purchased 222,873 MasterCraft Boat Holdings shares from March 14 through April 11 at prices ranging from $20.66 to $22.05 apiece. Following the purchases, Coliseum now owns 13.1% of MasterCraft Boat Holdings' outstanding stock. Shares have lost roughly 5% year to date.
Decreases in Holdings
SentinelOne Insight Venture Partners X reduced its stake in the cybersecurity firm to 24,146,230 shares. That figure consists of 18,873,681 Class B shares and another 5,272,549 Class A shares. Class B shares carry 20 votes each, and the Class A shares carry one vote each; Class B shares, which don't trade publicly, can be converted into Class A shares in order to be sold. Insight Venture converted 8,610,919 Class B shares into an equal number of Class A shares, and sold 3,500,000 Class A shares from April 1 through April 9 at prices ranging from $22.01 to $23.36 apiece.
Following the sales, Insight continues to own 8.2% of SentinelOne's outstanding stock. Shares of SentinelOne have lost roughly 13.1% during the year.
TD Synnex Apollo Management exited its stake in the technology distributor through the sale of 5,309,299 shares at $114.20 apiece in a secondary public offering on April 9. Apollo Management acquired a 45.4% stake in TD Synnex in September 2021, and began offloading shares aggressively in January 2024. Apollo Management has now sold 28,403,049 TD Synnex shares this year at prices ranging from $100.50 to $114.20 apiece.
Following the latest sale, Apollo Management no longer owns any TD Synnex shares, which have gained roughly 7.4% during the year.
Phathom Pharmaceuticals Takeda Pharmaceutical reduced its stake in the clinical-stage biopharmaceutical company to 2,790,480 shares. Takeda sold 362,737 Phathom Pharmaceuticals shares from April 1 through April 9 at prices ranging from $10.50 to $12.25 apiece. Takeda has been offloading its Phathom stake aggressively since January, with sales of 4,306,069 shares from Jan. 24 through March 28 at prices ranging from $8.10 to $11.40 apiece.
Following the sales, Takeda owns 4.8% of Phathom Pharmaceuticals' outstanding stock, below the 5% threshold that would require Takeda to report further sales. Shares have gained approximately 10.1% year to date.
Enliven Therapeutics 5AM Venture Management lowered its stake in the oncology-focused biotech to 2,835,875 shares. 5AM Venture Management did so through the sale of 1,000,100 Enliven Therapeutics shares on April 10 and April 11 at per share prices ranging from $20.28 to $24.51.
Following the sales, 5AM Venture Management continues to own 6.1% of Enliven Therapeutics' outstanding stock. Shares have gained roughly 35% during the year.
Email: editors@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 19, 2024 15:03 ET (19:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Comments